Power3 Working with Jordan University to Validate Breast Cancer Dx | GenomeWeb
NEW YORK (GenomeWeb News) – Proteomic diagnostics company Power3 Medical Products is collaborating with the Princess Haya Biotechnology Center at the Jordan University of Science and Technology for a clinical validation study of the company’s BC-SeraPro Breast Cancer diagnostic blood test.
 
Under the program, the Princess Haya center and Jordan University will provide breast cancer, benign breast disease, and age-matched control patient samples that the company will analyze using its panel of protein biomarkers.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.